The New American by
Absent regulatory approval, the Biden administration struck a $3.2 billion deal last week with Pfizer and its partner BioNTech for 105 million doses of experimental genetic therapeutics for Covid (aka āvaccineā), which could be delivered as soon as later this summer and continue into the fourth quarter of the year.
According to the June 29Ā announcementĀ on Pfizerās website, the doses will come in 3, 10, and 30 milligrams, which suggests that they will cover all āeligibleā demographics for the shot, including toddlers as young asĀ six-month-old. The shipment will likely include the adult dose, which will be designed to tackle the Omicron strain of Covid.
Reportedly, the average price per dose in the new deal has increased from the $19.50 per dose the government paid in its initial contract with Pfizer, and reached more than $30.47 per dose.
